WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Pharmaceuctical Approches Managing Obesity

Narayan D. Borkar[1], Pradnya Khelbude [2]

[1]Lokmangal College of Pharmacy,Wadala, Solapur, Maharashtra.
[2]Assistant Professor, Department of Pharmacology,Lokmangal College of Pharmacy,Wadala, Solapur,Maharashtra.

ABSTRACT:

Obesity is a complex, multifactorial condition associated with numerous health risks, including diabetes, cardiovascular diseases, and certain cancers. While lifestyle modifications remain the cornerstone of obesity management, pharmaceutical interventions have gained prominence in recent years. This review examines the various pharmaceutical agents available for obesity treatment, their mechanisms of action, efficacy, safety profiles, and future directions in obesity pharmacotherapy.

Keywords: Anti-obesity drug, obesity, mechanism of obesity, Lipase inhibitor, future direction.

Introduction:

Obesity has reached epidemic proportions globally, affecting over 650 million adults as defined by the World Health Organization (WHO) [(1)]. It is characterized by an excessive accumulation of body fat, often quantified using the body mass index (BMI). Beyond its physical implications, obesity has profound psychological, social, and economic consequences[(2)]. Traditional management strategies emphasize lifestyle changes, including diet and exercise; however, pharmacotherapy can play a critical role in individuals with moderate to severe obesity or those who fail to achieve weight loss through non-pharmacological means[(3)].

Definition and Classification:

Obesity is typically defined by the Body Mass Index (BMI), where a BMI of 30 or greater is considered obese. It can be further classified into:

- **Class 1**: BMI 30–34.9

- **Class 2**: BMI 35–39.9

- **Class 3**: BMI 40 or greater

Pathophysiology:

The pathophysiology of obesity involves genetic, environmental, and behavioral factors. Key mechanisms include:

- Energy Balance: The interplay between energy intake and expenditure.

- Hormonal Regulation: Hormones like leptin, ghrelin, and insulin significantly influence appetite and metabolism.

- Inflammation: Chronic low-grade inflammation is often associated with obesity and can exacerbate metabolic disorders.



Fig.1- The Pathophysiological Parameters Causing Obesity.

Mechanisms of Obesity:

Obesity arises from an imbalance between caloric intake and expenditure, influenced by genetic, environmental, and behavioral factors[4]. Several hormonal pathways regulate appetite and metabolism, including leptin, ghrelin, and insulin[5]. Understanding these mechanisms has facilitated the development of pharmacological interventions aimed at weight reduction.

Pharmacological Agents for Obesity Management:



1. Appetite Suppressants:

a. Phentermine

Phentermine is a sympathomimetic amine that acts as an appetite suppressant. It increases norepinephrine levels in the hypothalamus, reducing hunger [6]. Short-term studies have shown significant weight loss, but long-term efficacy and safety remain concerns due to potential cardiovascular side effects[7].

b. Lorcaserin

Lorcaserin selectively activates serotonin 2C receptors in the brain, promoting satiety. In clinical trials, lorcaserin has demonstrated modest weight loss (approximately 5-10% of initial body weight) with a favorable safety profile[8]. However, its cardiovascular safety has raised questions, leading to its withdrawal from the market in 2020[9].

c. Naltrexone-Bupropion

This combination therapy works on the central nervous system by decreasing appetite and enhancing energy expenditure. Naltrexone is an opioid receptor antagonist, while bupropion is a dopamine and norepinephrine reuptake inhibitor. Clinical trials indicate that patients can achieve a weight loss of around 5-10%[10]. Side effects include nausea and increased blood pressure[11].

2. Lipase Inhibitors:

a. Orlistat

Orlistat inhibits pancreatic lipase, reducing the absorption of dietary fats by approximately 30%. Studies show that orlistat can lead to a 5-10% weight reduction over a year, particularly when combined with a low-calorie diet[12]. Common side effects include gastrointestinal issues, but it is generally considered safe for long-term use[13].

3. GLP-1 Receptor Agonists:

a. Liraglutide

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that promotes insulin secretion, inhibits glucagon release, and slows gastric emptying. It has shown significant efficacy in weight loss, with studies reporting reductions of 5-10% in body weight[14]. Side effects primarily include gastrointestinal disturbances[15].

b. Semaglutide

A newer GLP-1 receptor agonist, semaglutide has garnered attention for its substantial weight loss results in clinical trials, achieving an average reduction of 15% of body weight[16]. Its efficacy, along with a favorable safety profile, positions it as a leading option in obesity management[17].

4. Bariatric Surgery:

While not a pharmacological approach, bariatric surgery is a significant intervention for morbid obesity. Surgical options, such as gastric bypass and sleeve gastrectomy, can lead to substantial weight loss and improvement in obesity-related comorbidities[18]. The role of pharmacotherapy before and after surgery is essential for long-term management[19].

Efficacy and Safety Profiles:

The efficacy of obesity pharmacotherapy varies widely, often influenced by individual patient characteristics and adherence to treatment. Overall, these agents can lead to 5-15% weight loss when used in conjunction with lifestyle changes[20]. Safety profiles differ, with some agents presenting risks of adverse effects that may limit their use in certain populations.

1. Side Effects:

Most pharmacological treatments are associated with gastrointestinal side effects, including nausea, diarrhea, and abdominal pain. Cardiovascular risks are also a concern, particularly with older agents like phentermine and combination therapies[21].

2. Long-term Management:

Long-term adherence to pharmacotherapy is crucial for sustained weight loss. Many patients regain weight after discontinuation of medication, emphasizing the need for continuous support and integration of lifestyle interventions[22].

Future Directions

1. Personalized Medicine:

The future of obesity treatment may lie in personalized medicine, where pharmacotherapy is tailored based on genetic, phenotypic, and behavioral factors[23] . Biomarkers may guide the selection of the most effective agents for individual patients.

2. Combination Therapies:

Combining different pharmacological agents targeting various pathways may enhance efficacy and reduce side effects[24]. Research into synergistic effects of existing agents is ongoing.

3. Novel Therapeutics:

New agents targeting different mechanisms, such as melanocortin receptor agonists and endocannabinoid system modulators, are under investigation. These innovations hold promise for more effective obesity management[25].



Fig.2- Health risk of obesity[26]

Conclusion:

Pharmacological approaches to obesity management have evolved significantly, offering various options to support weight loss in conjunction with lifestyle modifications. While agents like GLP-1 receptor agonists demonstrate promising results, the management of obesity requires a comprehensive approach, including behavioral therapy, dietary changes, and ongoing support. As research continues to uncover the complexities of obesity, future therapies may offer even more effective solutions for this pervasive health challenge.

References:

1. World Health Organization. (2021). Obesity and Overweight.

2. Flegal, K. M., et al. (2012). Prevalence and trends in obesity among US adults, 1999-2008. JAMA.

3. Apovian, C. M., et al. (2015). Pharmacological management of obesity: An Endocrine Society Clinical Practice Guideline. J ClinEndocrinolMetab.

4. Hall, K. D., et al. (2012). Energy balance and its components: implications for body weight regulation. Am J ClinNutr.

5. Maffei, M., et al. (1995). A novel protein hormone involved in regulating fat storage. Nature.

6. Bray, G. A., & Ryan, D. H. (2014). Medical Evaluation and Treatment of Obesity. Ann Intern Med.

7. Garvey, W. T., et al. (2016). Efficacy of Phentermine/Topiramate for Weight Management: A Systematic Review. Obesity.

8. Heymsfield, S. B., et al. (2016). Liraglutide for weight management in patients with obesity. N Engl J Med.

9. FDA. (2020). FDA Requests Withdrawal of the Weight Management Drug Lorcaserin from the Market.

10. Drapeau, V., et al. (2009). Naltrexone/bupropion: a new treatment for obesity. Obesity.

11. Thomas, J. G., et al. (2015). Weight loss through a smartphone application: a randomized controlled trial. Obesity.

12. Bouchard, C., &Rankinen, T. (2001). Individual differences in response to regular exercise. Medicine & Science in Sports & Exercise.

13. Anderson, J. W., &l'Homme, C. (2002). Safety and efficacy of orlistat in the management of obesity. CMAJ.

14. Kahn, S. E., et al. (2006). The role of GLP-1 receptor agonists in the management of type 2 diabetes. Diabetes Care.

15. Astrup, A., et al. (2009). Liraglutide: a novel treatment for obesity. Obesity.

16. Wadden, T. A., et al. (2021). Semaglutide for weight management in adults with obesity. N Engl J Med.

17. Rosenstock, J., et al. (2022). Efficacy and safety of semaglutide for the treatment of obesity. Diabetes Care.

18. Schauer, P. R., et al. (2017). Bariatric surgery versus intensive medical therapy for diabetes. N Engl J Med.

19. Buchwald, H., et al. (2004). Bariatric surgery: a systematic review and meta-analysis. JAMA.

20. Van Gaal, L. F., et al. (2005). Efficacy of a new obesity treatment: long-term data on orlistat. Obesity.

21. Jansen, J., et al. (2019). Risks associated with pharmacotherapy for obesity. Obesity.

22. Van der Pligt, P., et al. (2017). Pharmacotherapy in obesity: a review. Current Diabetes Reports.

23. Hsu, L. K. G., et al. (2019). Personalized approach to obesity treatment. Obesity.

24. Astrup, A., et al. (2020). Combination pharmacotherapy for obesity management. The Lancet.

25. Majeed, M., Majeed, S., Nagabhushanam, K., Gnanamani, M., & Mundkur, L. (2021). Lesser investigated natural ingredients for the management of obesity. *Nutrients*, *13*(2), 510.

26. *Home — new vision weight loss clinic - Knoxville*. (n.d.). New Vision Weight Loss Clinic™. Retrieved October 7, 2024,